CLINICAL_TRIALS
trial_result
· 2009-10-09
Clinical Trial Update: Inhaled Apocynin Decreases Reactive Oxygen Species Concentrations in Exhaled Breath Condensate in Mild Asthmatics [Phase 1]
Summary
Phase 1 trial evaluating inhaled apocynin in mild asthma shows a reduction in reactive oxygen species in exhaled breath condensate.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Medical University of Lodz | Conditions: Bronchial Asthma | Phase 1 | Status: COMPLETED